Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.
In this study we evaluated the performance of the VERSANT HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes.
Derdelinckx
Inge
I
Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000, Leuven, Belgium.
Van Laethem
Kristel
K
Maes
Bart
B
Schrooten
Yoeri
Y
De Schouwer
Kirsten
K
De Wit
Stéphane
S
Fransen
Katrien
K
García Ribas
Sergio
S
Moutschen
Michel
M
Vaira
Dolores
D
Zissis
Georges
G
Van Ranst
Marc
M
Van Wijngaerden
Eric
E
Vandamme
Anne Mieke
AM
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001530:Belgium / Q000453:epidemiology; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D016333:HIV Protease / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000145:classification* / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests / Q000379:methods*; D009154:Mutation; D009693:Nucleic Acid Hybridization; D017422:Sequence Analysis, DNA / Q000379:methods
D019380:Anti-HIV Agents; D054303:HIV Reverse Transcriptase; D016333:HIV Protease